The Sleeping Beauty transposon system has been extensively tested for integration of reporter and therapeutic genes in vitro and in vivo in mice. Dogs were used as a large animal model for human therapy and minimally invasive infusion of DNA solutions. DNA solutions were delivered into the entire liver or the left side of the liver using balloon catheters for temporary occlusion of venous outflow. A peak intravascular pressure between 80 and 140 mmHg supported sufficient DNA delivery in dog liver for detection of secretable reporter proteins. Secretable reporters allowed monitoring of the time course of gene products detectable in the circulation postinfusion. Canine secreted alkaline phosphatase reporter protein levels were measured in plasma, with expression detectable for up to 6 weeks, while expression of canine erythropoietin was detectable for 7–10 days. All animals exhibited a transient increase in blood transaminases that normalized within 10 days; otherwise the treated animals were clinically normal. These results demonstrate the utility of a secreted reporter protein for real-time monitoring of gene expression in the liver in a large animal model but highlight the need for improved delivery in target tissues to support integration and long-term expression of Sleeping Beauty transposons.
Get full access to this article
View all access options for this article.
References
1.
RotheM, ModlichU, SchambachA. Biosafety challenges for use of lentiviral vectors in gene therapy. Curr Gene Ther, 2013; 13:453–68.
2.
SinghH, HulsH, KebriaeiP, CooperLJN. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev, 2014; 257:181–190.
3.
RaperSE, ChirmuleN, LeeFS, et al.Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 80:148–58.
4.
MannoCS, PierceGF, ArrudaVR, et al.Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med, 2006; 12:342–7.
5.
ZhangG, BudkerV, WolffJA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther, 1999; 10:1735–1737.
6.
LiuF, SongY, LiuD. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther, 1999; 6:1258–1266.
7.
KamimuraK, YokooT, AbeH, et al.Image-guided hydrodynamic gene delivery: Current status and future directions. Pharmaceutics. 2015; 7:213–223.
Podetz-PedersenKM, BellJB, SteeleTWJ, et al.Gene expression in lung and liver after intravenous infusion of polyethylenimine complexes of Sleeping Beauty transposons. Hum Gene Ther, 2010; 21:210–220.
10.
ZhangG, VargoD, BudkerV, et al.Expression of naked plasmid DNA injected into the afferent and efferent vessels of rodent and dog livers. Hum Gene Ther, 1997; 8:1722–1763.
11.
KamimuraK, KanefujiT, YokooT, et al.Safety assessment of liver-targeted hydrodynamic gene delivery in dogs. PLoS One, 2014; 9:e107203.
12.
EastmanSJ, BaskinKM, HodgesBL, et al.Development of catheter-based procedures for transducing the isolated rabbit liver with plasmid DNA. Hum Gene Ther, 2002; 13(17):2065–77.
13.
YoshinoH, HashizumeK, KobayashiE. Naked plasmid DNA transfer to the porcine liver using rapid injection with large volume. Gene Ther, 2006; 13(24):1696–702.
IvicsZ, HackettPB, PlasterkRH, etAl. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell, 1997; 91:501–510.
18.
AronovichEL, McIvorRS, HackettPB. The Sleeping Beauty transposon system: a non-viral vector for gene therapy. Hum Mol Genet, 2011; 20(R1):R14–R20.
19.
BoehmeP, DoernerJ, SolankiM, et al.The Sleeping Beauty transposon vector system for treatment of rare genetic diseases: an unrealized hope?. Curr Gene Ther, 2015; 15:255–265.
20.
OhlfestJR, FrandsenJL, FritzS, et al.Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood, 2005; 105:2691–8.
21.
YantSR, MeuseL, ChiuW, et al.Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet, 2000; 25:35–41.
22.
MikkelsenJG, YantSR, MeuseL, et al.Helper-Independent Sleeping Beauty transposon-transposase vectors for efficient nonviral gene delivery and persistent gene expression in vivo. Mol Ther, 2003; 8:654–665.
23.
MontiniE, HeldPK, NollM, et al.In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther, 2002; 6:759–769.
24.
WilberA, WangensteenKJ, ChenY, et al.Messenger RNA as a Source of Transposase for Sleeping Beauty Transposon-mediated Correction of Hereditary Tyrosinemia Type I. Mol Ther, 2007; 15:1280–1287 L1– file:///C:/Documents and Settings.
25.
AronovichEL, BellJB, BelurLR, et al.Prolonged expression of a lysosomal enzyme in mouse liver after Sleeping Beauty transposon-mediated gene delivery: implications for non-viral gene therapy of mucopolysaccharidoses. J Gene Med, 2007; 9:403–415.
26.
AronovichEL, BellJB, KhanS a, et al.Systemic correction of storage disease in MPS I NOD/SCID mice using the Sleeping Beauty transposon system. Mol Ther, 2009; 17:1136–1144.
27.
OlsonER, HylandKA, BostromK, et al.Non-immunogenic, secretable canine reporters for long term gene expression studies in the dog using the Sleeping Beauty transposon system. Mol Ther, 2008; 16:S124.
28.
Podetz-PedersenKM, VezysV, SomiaN V, RussellSJ, McIvorRS. Cellular Immune Response Against Firefly Luciferase After Sleeping Beauty Mediated Gene Transfer In Vivo. Hum Gene Ther, 2014; 25:955–965.
29.
BeaglesKE, PetersonL, ZhangX, MorrisJ, KiemH-P. Cyclosporine inhibits the development of green fluorescent protein (GFP)-specific immune responses after transplantation of GFP-expressing hematopoietic repopulating cells in dogs. Hum Gene Ther, 2005; 16:725–33.
30.
EisenhaberB, BorkP, EisenhaberF. Prediction of potential GPI-modification sites in proprotein sequences. J Mol Biol, 1999; 292:741–58.
31.
MátésL, ChuahMKL, BelayE, et al.Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet, 2009; 41:753–761.
32.
WilberAC, FrandsenJL, GeurtsJL, et al.RNA as a source of transposase for Sleeping Beauty-mediated gene insertion and expression in somatic cells and tissues. Mol Ther, 2006; 13:625–639.
33.
WilberA, LinehanJL, TianX, et al.Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells, 2007; 25:2919–2927.
34.
GeurtsAM, YangY, ClarkKJ, et al.Gene transfer into genomes of human cells by the Sleeping Beauty transposon system. Mol Ther, 2003; 8:108–117.
35.
ClarkKJ, CarlsonDF, FosterLK, et al.Enzymatic engineering of the porcine genome with transposons and recombinases. BMC Biotechnol, 2007; 7:42.
36.
ScorePR, BelurLR, FrandsenJL, et al.Sleeping Beauty-mediated transposition and long-term expression in vivo: use of the LoxP/Cre recombinase system to distinguish transposition-specific expression. Mol Ther, 2006; 13:617–624.
37.
MarchioroTL, PorterKA, BrownBI, OtteJB, StarzlTE. The effect of partial portacaval transposition on the canine liver. Surgery, 1967; 61:723–32.
38.
KobayashiN, KuramotoT, YamaokaK, HashidaM, TakakuraY. Hepatic uptake and gene expression mechanisms following intravenous administration of plasmid DNA by conventional and hydrodynamics-based procedures. J Pharmacol Exp Ther, 2001; 297:853–860.
39.
RandolphJE, StokolT, ScarlettJM, MacleodJN. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am J Vet Res, 1999; 60:636–642.
40.
FabreJW, GrehanA, WhitehorneM, et al.Hydrodynamic gene delivery to the pig liver via an isolated segment of the inferior vena cava. Gene Ther, 2008; 15:452–62.
41.
SawyerGJ, RelaM, DavenportM, et al.Hydrodynamic gene delivery to the liver: theoretical and practical issues for clinical application. Curr Gene Ther, 2009; 9:128–35.
42.
ZhangG, GaoX, SongYK, et al.Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther, 2004; 11:675–682.
43.
HackettPB, AronovichEL, HunterD, et al.Efficacy and safety of Sleeping Beauty transposon-mediated gene transfer in preclinical animal studies. Curr Gene Ther, 2011; 11:341–349.
44.
KobayashiN, NishikawaM, HirataK, TakakuraY. Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med, 2004; 6:584–592.
45.
CenterSA. Interpretation of liver enzymes. Vet Clin North Am Small Anim Pract, 2007; 37:297–333, vii.
46.
SummersC, RankinSM, CondliffeAM, et al.Neutrophil kinetics in health and disease. Trends Immunol, 2010; 31:318–24.
47.
KoliosG, ValatasV, KouroumalisE. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol, 2006; 12(46):7413–20.
48.
HamanoT, TongV, MutaiM, HayashiM, TanakaE. Kupffer cell- mediated cytotoxicity induced by lipopolysaccharide0111:B4 is greater in dogs. J Toxicol Sci, 2002; 27:1–9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
